The ROS/SUMO Axis Contributes to the Response of Acute Myeloid Leukemia Cells to Chemotherapeutic Drugs

Cell Reports

Volumn 7, Issue 6, 2014, Pages 1815-1823

  Bossis, Guillaume ^a   Sarry, Jean Emmanuel ^b   Kifagi, Chamseddine ^a   Ristic, Marko ^a   Saland, Estelle ^b   Vergez, François ^b   Salem, Tamara ^a   Boutzen, Héléna ^b   Baik, Hayeon ^a   Brockly, Frédérique ^a   Pelegrin, Mireia ^a   Kaoma, Tony ^d   Vallar, Laurent ^d   Récher, Christian ^b,c   Manenti, Stéphane ^b   Piechaczyk, Marc ^a  

^a INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

^b INSERM   (France)

^c TOULOUSE UNIVERSITY HOSPITAL   (France)

^d LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

ANACARDIC ACID; ANTINEOPLASTIC AGENT; CASPASE 3; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; REACTIVE OXYGEN METABOLITE; SUMO 1 PROTEIN; SUMO 2 PROTEIN; SUMO 3 PROTEIN; SUMO PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONJUGATION; CONTROLLED STUDY; DDIT3 GENE; DESUMOYLATION; DRUG EFFECT; EMBRYO; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA CELL; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; ANIMAL; DISEASE MODEL; DRUG SCREENING; HL 60 CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MICROARRAY ANALYSIS; NUDE MOUSE; U937 CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYTARABINE; DAUNORUBICIN; DISEASE MODELS, ANIMAL; ETOPOSIDE; FEMALE; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MICE; MICE, NUDE; MICROARRAY ANALYSIS; REACTIVE OXYGEN SPECIES; SUMO-1 PROTEIN; U937 CELLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84903388394     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.05.016     Document Type: Article

References (35)

1. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J.R. Stat. Soc. 1995, 57:289-300.
2. Bettermann K., Benesch M., Weis S., Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett. 2012, 316:113-125.
3. Block K., Gorin Y. Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 2012, 12:627-637.
4. Bossis G., Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 2006, 21:349-357.
5. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N.Engl. J. Med. 2013, 368:2059-2074. Cancer Genome Atlas Research Network.
6. Cubeñas-Potts C., Matunis M.J. SUMO: a multifaceted modifier of chromatin structure and function. Dev. Cell 2013, 24:1-12.
7. Driscoll J.J., Pelluru D., Lefkimmiatis K., Fulciniti M., Prabhala R.H., Greipp P.R., Barlogie B., Tai Y.-T., Anderson K.C., Shaughnessy J.D., et al. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood 2010, 115:2827-2834.
8. Estey E.H. Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am. J. Hematol. 2012, 87:89-99.
9. Eymin B., Dubrez L., Allouche M., Solary E. Increased gadd153 messenger RNA level is associated with apoptosis in human leukemic cells treated with etoposide. Cancer Res. 1997, 57:686-695.
10. Feligioni M., Nisticò R. SUMO: a (oxidative) stressed protein. Neuromolecular Med. 2013, 15:707-719.
11. Flotho A., Melchior F. Sumoylation: a regulatory protein modification in health and disease. Annu. Rev. Biochem. 2013, 82:357-385.
12. Fukuda I., Ito A., Hirai G., Nishimura S., Kawasaki H., Saitoh H., Kimura K., Sodeoka M., Yoshida M. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 2009, 16:133-140.
13. Gewirtz D.A. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol. 1999, 57:727-741.
14. Hole P.S., Darley R.L., Tonks A. Do reactive oxygen species play a role in myeloid leukemias?. Blood 2011, 117:5816-5826.
15. Jackson S.P., Durocher D. Regulation of DNA damage responses by ubiquitin and SUMO. Mol. Cell 2013, 49:795-807.
16. Jeanne M., Lallemand-Breitenbach V., Ferhi O., Koken M., Le Bras M., Duffort S., Peres L., Berthier C., Soilihi H., Raught B., de Thé H. PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell 2010, 18:88-98.
17. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
18. Krogh-Madsen M., Hansen S.H., Honoré P.H. Simultaneous determination of cytosine arabinoside, daunorubicin and etoposide in human plasma. J.Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2010, 878:1967-1972.
19. Lagadinou E.D., Sach A., Callahan K., Rossi R.M., Neering S.J., Minhajuddin M., Ashton J.M., Pei S., Grose V., O'Dwyer K.M., et al. BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. Cell Stem Cell 2013, 12:329-341.
20. Maere S., Heymans K., Kuiper M. BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics 2005, 21:3448-3449.
21. Matés J.M., Segura J.A., Alonso F.J., Márquez J. Oxidative stress in apoptosis and cancer: an update. Arch. Toxicol. 2012, 86:1649-1665.
22. Michaud H.-A., Gomard T., Gros L., Thiolon K., Nasser R., Jacquet C., Hernandez J., Piechaczyk M., Pelegrin M. A crucial role for infected-cell/antibody immune complexes in the enhancement of endogenous antiviral immunity by short passive immunotherapy. PLoS Pathog. 2010, 6:e1000948.
23. Moreau-Gachelin F. Lessons from models of murine erythroleukemia to acute myeloid leukemia (AML): proof-of-principle of co-operativity in AML. Haematologica 2006, 91:1644-1652.
24. Neyret-Kahn H., Benhamed M., Ye T., Le Gras S., Cossec J.-C., Lapaquette P., Bischof O., Ouspenskaia M., Dasso M., Seeler J., et al. Sumoylation at chromatin governs coordinated repression of a transcriptional program essential for cell growth and proliferation. Genome Res. 2013, 23:1563-1579.
25. Paulsen C.E., Carroll K.S. Orchestrating redox signaling networks through regulatory cysteine switches. ACS Chem. Biol. 2010, 5:47-62.
26. Pei S., Minhajuddin M., Callahan K.P., Balys M., Ashton J.M., Neering S.J., Lagadinou E.D., Corbett C., Ye H., Liesveld J.L., et al. Targeting aberrant glutathione metabolism to eradicate human acute myelogenous leukemia cells. J.Biol. Chem. 2013, 288:33542-33558.
27. Quillet-Mary A., Mansat V., Duchayne E., Come M.G., Allouche M., Bailly J.D., Bordier C., Laurent G. Daunorubicin-induced internucleosomal DNA fragmentation in acute myeloid cell lines. Leukemia 1996, 10:417-425.
28. Raman N., Nayak A., Muller S. The SUMO system: a master organizer of nuclear protein assemblies. Chromosoma 2013, 122:475-485.
29. Rosonina E., Duncan S.M., Manley J.L. SUMO functions in constitutive transcription and during activation of inducible genes in yeast. Genes Dev. 2010, 24:1242-1252.
30. Smyth G. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, 397-420. Springer, New York.
31. Tan J., Chen B., He L., Tang Y., Jiang Z., Yin G., Wang J., Jiang X. Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling. Chin. J. Cancer Res. 2012, 24:275-283.
32. Tempé D., Piechaczyk M., Bossis G. SUMO under stress. Biochem. Soc. Trans. 2008, 36:874-878.
33. Tempé D., Vives E., Brockly F., Brooks H., De Rossi S., Piechaczyk M., Bossis G. SUMOylation of the inducible (c-Fos:c-Jun)/AP-1 transcription complex occurs on target promoters to limit transcriptional activation. Oncogene 2014, 33:921-927.
34. Vergez F., Green A.S., Tamburini J., Sarry J.-E., Gaillard B., Cornillet-Lefebvre P., Pannetier M., Neyret A., Chapuis N., Ifrah N., et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica 2011, 96:1792-1798.
35. Yang W., Wang L., Roehn G., Pearlstein R.D., Ali-Osman F., Pan H., Goldbrunner R., Krantz M., Harms C., Paschen W. Small ubiquitin-like modifier 1-3 is activated in human astrocytic brain tumors and is required for glioblastoma cell survival. Cancer Sci. 2013, 104:70-77.